Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14941123 | 0.99 | GPR119 (0.98) | GPR119CYP2C9 | |
| SCHEMBL4727227 | 0.90 | GPR119 (0.81) | GPR119CYP2C9 | |
| SCHEMBL4727336 | 0.89 | GPR119 (0.80) | GPR119CYP2C9 | |
| SCHEMBL12276208 | 0.87 | GPR119 (0.78) | GPR119 | |
| SCHEMBL15388540 | 0.87 | GPR119 (0.76) | GPR119 | |
| SCHEMBL13107758 | 0.86 | GPR119 (0.74) | GPR119CYP2C9 | |
| SCHEMBL389518 | 0.86 | GPR119 (0.76) | GPR119CYP2C9 | |
| SCHEMBL4263519 | 0.85 | GPR119 (0.75) | GPR119CYP2C9 | |
| SCHEMBL12276163 | 0.85 | GPR119 (0.86) | GPR119 | |
| SCHEMBL12273805 | 0.85 | GPR119 (1.00) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-21 | — | — | US | claimed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8513264-B2 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2344195-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100160359-A1 | Modulators of Metabolism and the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160359-A1 | Modulators of Metabolism and the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1931654-B1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1931654-B1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-101263135-A | Modulators of metabolism and treatment of metabolic-related disorders | ARENA PHARM INC (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1931654-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1931654-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007035355-A3 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007035355-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035355-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035355-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160359-A1 | Modulators of Metabolism and the Treatment of Disorders Related Thereto | GPR119, PC, SLC5A1 | GPR119 1/4885CYP2C9 423/4885 |
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885CYP2C9 2287/4885 |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885CYP2C9 2459/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885CYP2C9 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.